Anthos was launched by Novartis and Blackstone (BX) unit Blackstone Life Sciences in 2019. The firm has exclusive global rights from Novartis to develop, manufacture and commercialize abelacimab ...

Swiss pharmaceutical giant Novartis announced Thursday that it plans to build a $1.1 billion research hub in San Diego as ...

Anthos was founded by Blackstone Life Sciences and Novartis in 2019 with the exclusive global rights from Novartis to develop, manufacture, and commercialize abelacimab, a novel Factor XI ...

part of Blackstone (NYSE:BX) and Novartis (NYSE:NVS). Anthos was given exclusive global rights from Novartis (NVS) to develop ...

Novartis has agreed to buy Anthos Therapeutics from private equity firm Blackstone for $3.1 billion, adding a drug in late-stage clinical testing to prevent complications in patients with atrial ...

CAMBRIDGE, Mass., February 11, 2025--Blackstone Life Sciences and Anthos Therapeutics Announce Agreement for Anthos to be Acquired by Novartis for up to $3.1 billion Acushnet Holdings Corp. (NYSE ...

Then Skr739 per month. Complete digital access to quality FT journalism on any device. Cancel anytime during your trial.

In 2022, Novartis said it would cut 8,000 jobs globally, Reuters reported, which would save the company $1 billion over the next two years Global drugmaker Novartis will lay off 427 employees who ...